Table 3. Overview of mean levels of PBMC AKT1 expression levels (log-transformed relative intensity values) between patients and controls and between patient subgroups.

	Controls	Patients (all)	Patients (acute) vs patients (stabilized)	Patients (antipsychotic naïve)	Patients (antipsychotic free>2 weeks)	Patients (medicated)	Patients using nicotine vs non-nicotine	Patients using cannabis vs non-cannabis
	(N = 29)	(N = 41)	(N = 20, N = 21)	(N = 6)	(N = 11)	(N = 30)	(N = 26, N = 15)	(N = 18, N = 23)
AKT1 expression(mean ± sd)	580.48±57.91	518.58±61.46*	528.92±67.34 vs 508.73±55.13†	481.81±41.23‡	493.33±55.09‡	526.72±62.01*	530.45±58.31 vs 98.00±63.29††	522.97±65.88 vs 515.14±59.05‡‡

^*p<0.001 as compared to the controls (t-test).

^†non-significant difference between acutely admitted patients vs stabilized patients.

^††non-significant difference between nicotine and non-nicotine.

^‡non-significant difference as compared to medicated patients.

^‡‡non-significant difference between cannabis abuse vs non-cannabis abuse.